×
About 7,895 results

ALLMedicine™ Myelodysplastic Syndrome Center

Research & Reviews  2,555 results

Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myel...
https://doi.org/10.1016/j.clml.2021.10.015
Clinical Lymphoma, Myeloma & Leukemia; Polprasert C, Niparuck P et. al.

Nov 30th, 2021 - Unexplained cytopenia (UC) and low-risk myelodysplastic syndrome (MDS) are distinguished mainly by morphologic dysplasia, which sometimes shows inter-observer discrepancy. We hypothesized that gene mutations are strong prognostic factors for these...

Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic ...
https://doi.org/10.1111/ijlh.13771
International Journal of Laboratory Hematology; Pembroke JS, Joseph JE et. al.

Nov 30th, 2021 - The myelodysplastic syndromes (MDSs) are heterogeneous myeloid malignancies, conventionally diagnosed by cytomorphology and cytogenetics, with an emerging role for flow cytometry. This study compared the performance of a 4-parameter flow cytometry...

Percutaneous left atrial appendage closure in patients with primary hemostasis disorder...
https://doi.org/10.1007/s10840-021-01073-0 10.1378/chest.09-1584 10.1097/FJC.0000000000000607 10.1111/hae.12445 10.1007/s11239-020-02097-5 10.1111/hae.12055 10.1016/j.hrcr.2019.01.014 10.1111/ejh.13296 10.1053/spen.2000.20075 10.1111/jth.12916 10.1111/j.1538-7836.2005.01204.x 10.1111/j.1538-7836.2009.03678.x 10.1056/NEJMcp1810479 10.1016/j.leukres.2005.03.004 10.1055/s-0039-1698756
Journal of Interventional Cardiac Electrophysiology : an ... Dognin N, Salaun E et. al.

Nov 26th, 2021 - We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD). Consecutive patients with primary HD who underwent a perc...

Radium-223 Dichloride Long-term Follow-up Program
https://clinicaltrials.gov/ct2/show/NCT02312960

Nov 25th, 2021 - This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of rad...

Toward a pathophysiology inspired treatment of VEXAS syndrome.
https://doi.org/10.1053/j.seminhematol.2021.09.001
Seminars in Hematology; Heiblig M, Patel BA et. al.

Nov 23rd, 2021 - VEXAS syndrome has an unmet need for therapeutic interventions. Even if few data exist regarding the treatment of this newly described syndrome, different options can be proposed given the unique pathophysiological consequences of the clonal domin...

see more →

Guidelines  2 results

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellula...
https://doi.org/10.3324/haematol.13755
Haematologica Bennett JM, Orazi A

Jan 16th, 2009 - Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three wo...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  247 results

Radium-223 Dichloride Long-term Follow-up Program
https://clinicaltrials.gov/ct2/show/NCT02312960

Nov 25th, 2021 - This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of rad...

Study to Evaluate CCS1477 in Haematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04068597

Nov 23rd, 2021 - A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Sub...
https://clinicaltrials.gov/ct2/show/NCT03682536

Nov 22nd, 2021 - Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platel...

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia
https://clinicaltrials.gov/ct2/show/NCT05126849

Nov 19th, 2021 - Outcomes for patients with severe aplastic anemia (SAA) who are refractory to first-line immunosuppressive therapy (IST) and who lack a matched unrelated donor (MUD) remain poor. Recently, the use of eltrombopag (ELT) has shown blood count improve...

A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT05107856

Nov 18th, 2021 - This is a multicenter, open-label, dose-escalation Phase 1 study of PRT1419, a MCL1 inhibitor, evaluating patients as part of a 28-day treatment cycle in adult patients with acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), hig...

see more →

News  320 results

Incorporating Mutational Panel Testing Remains Crucial in MDS
https://www.onclive.com/view/incorporating-mutational-panel-testing-remains-crucial-in-mds

Nov 24th, 2021 - Next-generation sequencing (NGS) and broad-base mutational panels can improve understanding of a patient’s disease and inform treatment decisions, therefore mutational testing should be incorporated early into the treatment of those with myelodysp...

Quizartinib/Chemo Shows Superior OS Benefit Over Chemo Alone in Newly Diagnosed FLT3-ITD+ AML
https://www.onclive.com/view/quizartinib-chemo-shows-superior-os-benefit-over-chemo-alone-in-newly-diagnosed-flt3-itd-aml

Nov 19th, 2021 - The addition of quizartinib to standard induction and consolidation chemotherapy followed by quizartinib monotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) vs standard chemotherapy al...

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

Autologous HSCT Shows Sustained Long-Term Benefit in MCL, But Role May Be Rechallenged By Novel Approaches
https://www.onclive.com/view/autologous-hsct-shows-sustained-long-term-benefit-in-mcl-but-role-may-be-rechallenged-by-novel-approaches

Oct 11th, 2021 - Autologous hematopoietic stem-cell transplantation (HSCT) maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma (MCL), confirming its place as the standard frontline treatment in this population, according to...

see more →

Patient Education  5 results see all →